At least three GPVI isoforms are known to exist, this antibody will detect the two longest isoforms. Because of its extensive glycosylation, GPVI often migrates at a higher than expected molecular weight in SDS-PAGE.
Purification
GPVI Antibody is affinity chromatography purified via peptide column.
Immunogen
GPVI antibody was raised against a 15 amino acid synthetic peptide near the carboxy terminus of isoform 2 of the human GPVI. The immunogen is located within the last 50 amino acids of GPVI.
GP6
Reactivity: Human, Mouse, Rat
WB, IF (p)
Host: Rabbit
Polyclonal
Alexa Fluor 750
Application Notes
GPVI antibody can be used for detection of GPVI by Western blot at 1 μ,g/mL. Antibody can also be used for immunohistochemistry starting at 10 μ,g/mL. For immunofluorescence start at 20 μ,g/mL.
Antibody validated: Western Blot in mouse samples, Immunohistochemistry in human samples and Immunofluorescence in human samples. All other applications and species not yet tested.
Restrictions
For Research Use only
Format
Liquid
Concentration
1 mg/mL
Buffer
GPVI Antibody is supplied in PBS containing 0.02 % sodium azide.
Preservative
Sodium azide
Precaution of Use
This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
Storage
-20 °C,4 °C
Storage Comment
GPVI antibody can be stored at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.
GPVI Antibody: Glycoprotein VI (GP6) is a 58kD platelet membrane glycoprotein that plays a crucial role in the collagen-induced activation and aggregation of platelets. It is uniquely expressed by cells of the megakaryocytic/platelet lineage, and is a member of the immunoglobulin gene superfamily, closely related to Fc receptor gamma chain (FcRgamma) and natural killer receptors. Glycoprotein VI plays a key role in platelet procoagulant activity and subsequent thrombin and fibrin formation. This procoagulant function may contribute to arterial and venous thrombus formation. The signaling pathway involves the FcRgamma, the Src kinases (likely Fyn/Lyn), the adapter protein LAT and leads to the activation of phospholipase C gamma2. GPVI deficiency can result in bleeding disorders. Further study should reveal the extent of GPVI involvement in thrombotic disease and allow the development of alternative anti-thrombotic compounds.